SCHEMBL27213630

SCHEMBL27213630

CN(Cc1ccc(Oc2ccc(C#N)cc2)cc1)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.55
PARP15 Q460N3 1/20 0.50
PARP10 Q53GL7 1/20 0.50
PARP2 Q9UGN5 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
RAB9A P51151 2/20 0.49
KDM4E B2RXH2 2/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
PKM P14618 1/20 0.49
MAPK1 P28482 1/20 0.49
IL18 Q14116 1/20 0.49
SNCA P37840 1/20 0.48
NR3C1 P04150 2/20 0.48
PGR P06401 1/20 0.48
MMP2 P08253 1/20 0.48
MAOB P27338 1/20 0.47
SLC6A4 P31645 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118098 0.91 NSD2 (0.63) NSD2MEN1KMT2ARAB9APOLB
SCHEMBL30947346 0.84 NSD2 (0.48) NSD2PARP15PARP10PARP2MEN1
SCHEMBL5317577 0.79 NSD2 (0.61) NSD2MEN1KMT2AMAPTPOLB
SCHEMBL5317572 0.78 NSD2 (0.60) NSD2MEN1KMT2APOLBSNCA
SCHEMBL6917099 0.78 SRD5A2 (0.57) PARP15PARP10PARP2MEN1KMT2A
SCHEMBL6800966 0.77 NSD2 (0.71) NSD2MEN1KMT2ARAB9AMAPK1
SCHEMBL21595642 0.77 MMP2 (0.67) KDM4EMAPTPOLBMMP2MAOB
SCHEMBL19049393 0.76 NSD2 (0.58) NSD2MEN1KMT2ARAB9AKDM4E
SCHEMBL6163419 0.76 NSD2 (0.58) NSD2KMT2ARAB9AKDM4EMAPT
SCHEMBL14540450 0.75 NSD2 (0.57) NSD2MEN1KMT2ARAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 NSD2 4618/4885PARP15 2079/4885PARP10 2077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.